Cullinan Therapeutics, Inc. · NASDAQ:CGEM

Cullinan Therapeutics — Investor Presentation (October 2026)

64 slides from Cullinan Therapeutics's investor presentation, October 2026

  1. Slide 1: Corporate Overview

    CORPORATE OVERVIEW October 2026

  2. Slide 2: Important Notice and Disclaimers

    Important Notice and Disclaimers This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including express or implied statements regardin

  3. Slide 3: Leading T Cell Engager Portfolio Across Immunology and Oncology

    Leading T Cell Engager Portfolio of Potential Best-In-Class Clinical Stage Programs Across Immunology and Oncology T cell engagers engineered against high-impact, validated targets, with best-in-class, disease-modifying potential CLN-978 Unmet Need in Immunology and Inflammation IMMUNOLOGY CD19xCD3

  4. Slide 4: Leveraging Novel Technologies and Differentiated Mechanisms Across Immunology and Oncology

    Leveraging Novel Technologies and Differentiated Mechanisms Across Immunology and Oncology Immunology Program Study Population IND-Enabling Phase 1 Phase 2 Phase 3 Status/ Next Milestone Geographic Rights Modality/MOA Systemic lupus Multi-dose regimen data in December; erythematosus (SLE) Initiate P

  5. Slide 5: T Cell Engagers in Autoimmune Diseases

    T CELL ENGAGERS IN AUTOIMMUNE DISEASES © Cullinan Therapeutics, Inc. All rights reserved. Confidential and proprietary. | 5

  6. Slide 6: Complementary Immunology Portfolio Designed to Expand Reach

    Complementary Immunology Portfolio Designed to Expand Reach To Broadest Range of Autoimmune Diseases BCMA is the optimal target for CLN-978 CD19 is the optimal target for B cell driven rheumatic diseases Velinotamig diseases driven by pathogenic autoantibodies • Potential best-in-class CD19 • Potent

  7. Slide 7: CLN-978: Going Deep Into Large, High Unmet Need Rheumatology Indications

    CLN-978: Going Deep Into Large, High Unmet Need Rheumatology Indications Validated markets with significant CLN-978 Opportunity remaining unmet need Rheumatologic Diseases >$3B • Currently approved biologics have modest efficacy and relatively limited uptake Systemic Lupus Erythematosus Rheumatoid A

  8. Slide 8: Velinotamig: Broad Expansion Opportunity in Plasma Cell Driven Diseases

    Velinotamig: Broad Expansion Opportunity to Address Diverse Plasma Cell Driven Diseases High unmet need indications representing Velinotamig Opportunity significant opportunities Nonmalignant Hematology • Hematology is sizeable market opportunity Autoimmune Hemolytic Anemia Immune Thrombocytopenia •

  9. Slide 9: CLN-978

    CLN-978 CD19xCD3 T cell engager © Cullinan Therapeutics, Inc. All rights reserved. Confidential and proprietary. | 9

  10. Slide 10: CLN-978: Bringing the Promise of Immune Reset to Autoimmune Patients

    CLN-978: Bringing the Promise of Immune Reset to the Broad Population of Patients with Autoimmune Diseases IMMUNE RESET POTENTI AL B R O AD C L I N I C A L I M P AC T O U T P AT I E N T AD M I N I S T R A T I O N Deep B cell depletion Clinical activity and Delivered as a medicine in the consistent w

  11. Slide 11: CLN-978 SLE and RA Dose Escalation Design

    CLN-978 SLE and RA Dose Escalation Design Single Ascending Dose Cohorts Multi-dose Cohorts SLE Study Population Patients discontinued chronic immunosuppressants 1. SLE meeting 2019 EULAR/ACR criteria at least 2 weeks prior to starting CLN-978 2. One or more of the following SLE autoantibodies: • ant

  12. Slide 12: Enrolled SLE and RA Patients Have Highly Refractory Disease

    Enrolled SLE and RA Patients Have Highly Refractory Disease SLE (n = 21) RA (n=11) Sex, n (%) Male 0 1 (9.1) Female 21 (100) 10 (90.9) Median age (range), years 43 (22, 61) 59 (45, 72) Ethnicity, n (%) Hispanic or Latino 4 (19.0) 0 Race, n (%) American Indian or Alaska Native 1 (4.8) 0 Asian 1 (4.8)

  13. Slide 13: CLN-978 Generally Well Tolerated Across Single and Multiple Target Doses

    CLN-978 Generally Well Tolerated Across Single Target Doses and Multiple Target Doses in SLE and RA Any grade Grade ≥ 3 N = 32 n (%) n (%) Number of Subjects with at least 1 TEAE 28 (87.5) 5 (15.6) Number of Subjects with Serious TEAE a 5 (15.6) 2 (6.3) Any grade TEAEs occurring in ≥ 3 patients: Cyt

  14. Slide 14: Primarily Grade 1 CRS Across Single and Multi-Dose Cohorts

    Primarily Grade 1 CRS Across Single and Multi-Dose Cohorts in Both SLE and RA Patients Cohort 5 RA Cohort 2 Cohort 3 Cohort 4 Cohort 1 Part B SLE (n = 10) (n = 10) (n = 1) CRS, n (n = 4) (n = 7) D1: 10µg D1: 10µg D1: 10µg D1: 10µg D1: 10µg D8: 20µg D8: 30µg D8: 45µg D8/15/22: 20µg Grade 1 0 5 2 0 4

  15. Slide 15: SLE: Disease-Modifying Efficacy with Single Target Doses of CLN-978

    SLE: Disease-Modifying Efficacy in Patients Observed with Single Target Doses of CLN-978 Among 14 patients with ≥4 weeks follow up, a ≥4-point reduction in hSLEDAI was observed in 10 patients (71%), with 5 achieving a DORIS remission Pt # (hSLEDAI-Day 1) Patient-level disease activity 12 (10) 10 µg

  16. Slide 16: SLE: Significant Biomarker Impact Aligns with Clinical Response

    SLE: Significant Biomarker Impact Aligns with Clinical Response and Underlying Disease Modification Anti-dsDNA, UPCR, Complement protein levels all improved after single target doses of CLN-978 anti-dsDNA antibody UPCR Complement C3 Complement C4 (patients > ULN at baseline) (patients > 0.5 mg/mg at

  17. Slide 17: SLE: Complete B Cell Depletion at Go-Forward Doses

    SLE: Complete B Cell Depletion at Go-Forward Doses, with Dose-Dependent Time to Recovery B-cell depletion B-cell recovery (Day 1 to 29) (Week 4 to 20) 200 200 150 150 Cells/ul Cells/ul 100 100 50 50 0 0 D1 1 D8 8 D15 15 D22 22 D29 29 0 4 8 12 16 20 Time (days) Time (weeks) Peripheral B cell counts w

  18. Slide 18: OUTRACE-SLE: Advancing Toward Registration-enabling Studies

    OUTRACE-SLE: Advancing Toward Registration-enabling Studies Monotherapy Efficacy Facilitates More Efficient Development COMPLETED Phase 2a Dose Selection Part A: Phase 1 Single Ascending Dose Complete Multi-Dose Cohorts Target Initiation in Early 2027 Objective Objective Identify candidate dosing re

  19. Slide 19: OUTRACE-SLE: Accelerating the Path Toward Future Registration

    OUTRACE-SLE: Accelerating the Path Toward Future Registration Across SLE Patient Populations • High unmet need despite recent introduction of less potent B cell depleting therapies Phase 2 Lupus Nephritis • Efficacy in Phase 2a could support special regulatory designations (e.g. BTD) and inform path

  20. Slide 20: RA: Robust Disease Impact in Heavily Pretreated Patients

    RA: Robust Disease Impact Observed in Heavily Pretreated Patients, Including Two Remissions Pt # (DAS28-ESR-Day 1) Patient DAS28-ESR Categories Over Time 10 µg 001 (7.0) 003 (5.5) 10 µg + 20 µg 004 (4.0) 005 (5.6) 006 (5.2) 10 µg + 30 µg 007 (5.5) Remission (<2.6) 7 prior DMARDs 008 (6.8) Low (≥2.6

  21. Slide 21: RA: CLN-978 Rapidly Reduced Autoantibody Levels

    RA: CLN-978 Rapidly Reduced Autoantibody Levels without Impacting Protective Vaccine Titers Reduction in autoantibody levels >50% of baseline were observed in most patients treated with 20 µg or 30 µg target doses (Cohorts 2 and 3) Cohort 1 (10 μg): (N=1) Cohort 2 (10 μg → 20 μg): (N=3) Cohort 3 (10

  22. Slide 22: RA: Complete B Cell Depletion at Go-Forward Doses

    RA: Complete B Cell Depletion at Go-Forward Doses, with Dose-Dependent Time to Recovery, Consistent with SLE Observations Peripheral B cell depletion BLOQ was achieved in 4/6 RA patients treated at target doses ≥20µg (Cohorts 2 and 3) B-cell depletion B-cell kinetics follow-up (Day 1 to 29) (Week 4

  23. Slide 23: RA: Profound B Cell Depletion in Synovium

    RA: ≥20 µg Target Doses Result in Profound B Cell Depletion in Synovium Post-treatment synovial biopsy (Day 29) No change in T- B-cell depletion Change in immune cell density in the pre-treatment (screening) vs post-treatment and B-cells Reduction in inflammation T-cell and T-cell synovial B-cell an

  24. Slide 24: RA: Target Dose Depleted B Cells in Lymph Node Tissue

    RA: 30 µg Target Dose Substantially Depleted B Cells in Lymph Node Tissue Lymph node B cell depletion in Patient 007 accompanied by clinical remission Post-treatment lymph node biopsy (Day 29) Architecture Residual Disrupted LN Change in immune cell density in the pre-treatment (screening) vs post-

  25. Slide 25: RA: First TCE to Demonstrate Complete Disruption of Follicular Architecture

    RA: CLN-978 is the First TCE to Demonstrate Complete Disruption of Follicular Architecture, Associated with Immune Reset Erlangen Precedent CLN-978 • Until now, CAR T only modality capable of completely • 30 ug dose achieved full disruption of follicular architecture, disrupting follicular architect

  26. Slide 26: OUTRACE-RA: Advancing Toward Registration-enabling Studies

    OUTRACE-RA: Advancing Toward Registration-enabling Studies Monotherapy Efficacy Facilitates More Efficient Development COMPLETED Phase 2a Dose Selection Complete Multi-Dose Cohorts Target Initiation in Early 2027 Part A: Phase 1 Single Ascending Dose Objective Objective Identify candidate dosing reg

  27. Slide 27: OUTRACE-SjD Study Design

    OUTRACE-SjD Study Design Study Population Part A: Single Ascending Dose Study Multi-Dose Cohorts Objectives 1. Sjögren’s disease meeting Objective Primary Objective: 2016 EULAR/ACR criteria Identify candidate dosing regimens for further study Safety and tolerability of with a disease duration ≥ 24 C

  28. Slide 28: Velinotamig

    VELINOTAMIG BCMAxCD3 T cell engager © Cullinan Therapeutics, Inc. All rights reserved. Confidential and proprietary. | 28

  29. Slide 29: Velinotamig Unlocks Broad Opportunities in Autoantibody-driven Disorders

    Velinotamig Unlocks Broad Opportunities in Plasma-cell Derived Autoantibody-driven Disorders Velinotamig: BCMAxCD3 T Cell Engager Strategic Rationale and Development Status Genrix Bio autoimmune development in ongoing China Phase 1/2 study unlocks further opportunity: • Initial data from Genrix stud

  30. Slide 30: Genrix Phase 1b/2a Study in Refractory SLE

    Genrix Phase 1b/2a Study Explores Defined Duration, Multi-dose Regimens of Velinotamig in Patients With Refractory SLE Genrix Bio is conducting this study at 5 sites in China Dose Escalation Study Design Treatment Schedule Patient Eligibility Treatment Period: 4 doses administered IV over 4 weeks •

  31. Slide 31: Velinotamig Demonstrated Convincing Initial Efficacy

    Velinotamig Demonstrated Convincing Initial Efficacy Rapid clinical improvement observed at the starting dose level (10 ug), including rapid declines in proteinuria Initial Clinical Efficacy: Rapid and robust reductions in SLEDAI-2K and proteinuria SLEDAI-2K Proteinuria 18 2500 16 14 2000 12 Urine p

  32. Slide 32: Velinotamig Initial Efficacy Correlated with Key Biomarkers

    Velinotamig Initial Efficacy Correlated with Impact on Key Biomarkers Clinical response correlated with rapid decline in both normal and pathogenic antibodies Pharmacodynamics: Total IgG and dsDNA reduction, B cell depletion, and complement normalization Peripheral Blood B Cells Total IgG 70 20 60 B

  33. Slide 33: Velinotamig Demonstrates Favorable Initial Safety

    Velinotamig Demonstrates Favorable Initial Safety at Clinically Active Doses When Administered in a Multi-dose, Defined Duration Regimen Favorable safety at the clinically active initial dose level: No CRS or ICANS in first two patients Patient 1​ Patient 2​ CRS None​ None​ ICANS None None SAEs None

  34. Slide 34: Velinotamig: Initial Data Support Broad Potential

    Velinotamig: Initial Data Support Broad Potential In patients with refractory SLE, at the starting target dose of 10 mcg/kg, velinotamig demonstrated: Efficacy correlated with rapid Marked, antibody depleting depletion of pathogenic and Initial efficacy: complete renal effects achieved at a dose and

  35. Slide 35: Beyond Rheumatology: Global Development Plan in Autoimmune Cytopenias

    Beyond Rheumatology: Initial Genrix Data Informs Cullinan-led Global Development Plan in Autoimmune Cytopenias Initial focus on autoimmune cytopenias with high unmet need offers several advantages:  Exploits Cullinan’s existing hematology expertise and physician familiarity with both cytopenias and

  36. Slide 36: Advancing Velinotamig Global Clinical Development

    Advancing Velinotamig Global Clinical Development to Accelerate Upcoming Anticipated Milestones GLOBAL DEVELOPMENT STATUS Illustrative Autoimmune Cytopenia Study Design Dosing Follow Up Ongoing clinical development in I&I Day X X X X 52 weeks • Initiate Cullinan-led POC basket study in autoimmune cy

  37. Slide 37: CLN-049

    CLN-049 FLT3xCD3 T cell engager © Cullinan Therapeutics, Inc. All rights reserved. Confidential and proprietary. | 37

  38. Slide 38: Significant Unmet Need in Adult AML

    Significant Unmet Need in Adult AML • The only curative therapy is intensive chemotherapy +/- stem cell transplantation US AML incidence 22,2701 • Curative therapy remains out of reach for most AML patients: 85% patients >60 years old are ineligible for intensive chemotherapy • Recent treatment adva

  39. Slide 39: CLN-049 is an Optimal AML Immunotherapy

    CLN-049 is an Optimal AML Immunotherapy First-in-class opportunity: CLN-049 binds to the extracellular domain of 1 FLT3, both wildtype and mutated forms, redirecting a patient’s own T cells to CLN-049 binds to recognize and eliminate leukemic cells. both wild-type and mutant FLT3 Potential to treat

  40. Slide 40: CLN-049 Phase 1 Study in R/R AML or MDS

    CLN-049 Phase 1 Study in Patients with R/R AML or MDS: Initial Results from Dose-escalation Presented at ASH 2025 Study Design – IV Dose Escalation Cohorts Single SUD 3→6→12 µg/kg Study Objective Cohort n=4 Double SUD 1.5→6→12 µg/kg • To assess preliminary efficacy, safety, tolerability, PK, pharmac

  41. Slide 41: CLN-049 Phase 1: Enrolled Patients Representative of R/R AML Population

    CLN-049 Phase 1: Enrolled Patients Representative of the Broad R/R AML Population All cohorts 1→6 µg/kg cohort 1.5→9 µg/kg cohort 12 µg/kg cohorts1 Characteristic n=45 n=9 n=7 n=20 Diagnosis, n (%) AML 39 (87) 9 (100) 5 (71) 19 (95) MDS/AML 3 (7) 0 2 (29) 0 MDS 3 (7) 0 0 1 (5) ECOG at baseline, n (%

  42. Slide 42: CLN-049 Phase 1: Treatment-emergent Adverse Events

    CLN-049 Phase 1: Treatment-emergent Adverse Events Demonstrate a Favorable Safety Profile Single step-up cohorts Double step-up cohorts Total TEAEs by preferred term, 1→1.5 µg/kg 1→3 µg/kg 1→6 µg/kg 1.5→9 µg/kg 1→12 µg/kg 1→6→12 µg/kg 1.5→6→12 µg/kg 3→6→12 µg/kg n=45 >15% of patients, n (%) n=5 n=4

  43. Slide 43: CLN-049 Phase 1: Preliminary Efficacy Data

    CLN-049 Phase 1: Preliminary Efficacy Data Highlights Potential to Achieve Deep Responses in a Heavily Pre-treated Population Single step-up cohorts Double step-up cohorts Response All ≥6 µg/kg 12 µg/kg rate 1→1.5 1→3 1→6 1.5→9 1→12 1→6→12 1.5→6→12 cohorts cohorts cohorts (best response), µg/kg µg/k

  44. Slide 44: CLN-049 Phase 1: Initial Response Durability Data

    CLN-049 Phase 1: Promising Initial Response Durability Data 8 patients achieved CR or CRh at a TD of ≥6 µg/kg: • 5 patients had DoR >16 weeks • 3 MRD-negative patients all achieved DoR >16 weeks, including 1 patient with an ongoing response for >36 weeks • 2 additional patients attained CR and proce

  45. Slide 45: Recent Monotherapy Approvals in R/R AML Provide Efficacy Benchmarks

    Recent Monotherapy Approvals in R/R AML Provide Regulatory Efficacy Benchmarks for CLN-049 Development Gilteritinib1 Enasidenib2 Ivosidenib3 Revumenib4 Revumenib4 Ziftomenib5 Year approved 2018 2017 2018 2024 2025 2025 Target FLT3 IDH2 IDH1 KMT2A NPM1 NPM1 population AML Population ~30% ~8% to 12% ~

  46. Slide 46: CLN-049 Phase 2: Potentially Registrational Study in R/R AML

    CLN-049 Phase 2: Progressing to Potentially Registrational Phase 2 Study in R/R AML Phase 2 Dose Optimization and Expansion 6 µg/kg target dose n = up to 20 R/R AML • RP2D selection • All comer population 1:1 • No regulatory pause with Recommended Phase 2 Dose randomization n = 100 • ≤ 2 prior lines

  47. Slide 47: CLN-049: Expanding to Frontline AML in Combination with SOC

    CLN-049: Expanding to Frontline AML in Combination with SOC in Phase 1/2 Study Phase 1/2 Study Part A: Dose Escalation Study Objective CLN-049 Target dose initiated weekly after SUD • To assess preliminary efficacy, safety, tolerability, PK, regimen pharmacodynamics, and immunogenicity of IV-adminis

  48. Slide 48: CLN-049: Efficacy Enables Accelerated Approval Pathway and Commercial Opportunity

    CLN-049: Compelling Efficacy Enables Accelerated Approval Pathway and Drives Attractive Commercial Opportunity • CLN-049 is a first-in-class differentiated molecule • Initial efficacy data presented at ASH 2025 meets demonstrating compelling monotherapy efficacy the benchmark for recently approved a

  49. Slide 49: Zipalertinib (CLN-081/TAS6417)

    ZIPALERTINIB (CLN-081/TAS6417) EGFR ex20ins inhibitor © Cullinan Therapeutics, Inc. All rights reserved. Confidential and proprietary. | 49

  50. Slide 50: Zipalertinib: Profile for NSCLC Patients With EGFR Exon20 Insertion Mutations

    Zipalertinib: Compelling Profile for NSCLC Patients With EGFR Exon20 Insertion Mutations Potentially Best-in-Disease First-Line Option  Unprecedented 6-month improvement in median progression-free survival for zipalertinib plus chemotherapy over chemotherapy alone demonstrated early at interim anal

  51. Slide 51: REZILIENT3: Zipalertinib Plus Chemotherapy in First-Line EGFR exon20ins NSCLC

    REZILIENT3: Zipalertinib Plus Chemotherapy in First-Line EGFR exon20ins NSCLC Primary analysis: At 162 PFS events to detect HR 0.60, 2-sided α: 0.05, 90% power Part B: Randomized Phase 3 Pre-specified interim analysis: At 122 PFS events; if one-sided P<0.0098, superiority to be claimed Zipalertinib

  52. Slide 52: REZILIENT3: Patient Demographics and Baseline Characteristics

    REZILIENT3: Patient Demographics and Baseline Characteristics Zipalertinib + Chemotherapy Chemotherapy 1 (n=140) (n=139 ) Age, n (years) Median (range) 66.5 (30, 89) 64.0 (27, 82) Sex, n (%) Male 48 (34.3) 51 (36.7) Female 92 (65.7) 88 (63.3) Region, n (%) Asia 56 (40.0) 56 (40.3) Rest of world 84 (

  53. Slide 53: REZILIENT3: Median Progression-free Survival of 14.5 Months

    REZILIENT3: Unprecedented Median Progression-free Survival (PFS) of 14.5 Months per Blinded, Independent Central Review Probability of Progression-free Survival 100 Zipalertinib + Chemotherapy: Chemotherapy: Hazard Ratio: 90 Total: 140 Total: 139 0.50 (95% CI, 0.34-0.73) 80 14.5 (12.9, 21.4) 8.5 (7.

  54. Slide 54: REZILIENT3: Clinical Benefit in First-Line EGFR exon20ins NSCLC

    REZILIENT3: Clinical Benefit in First-Line EGFR exon20ins NSCLC Zipalertinib + chemotherapy demonstrated clinically meaningful efficacy in the first-line setting with a median DoR of 14.2 months – the best result observed to date in clinical trials for first-line EGFR exon20ins NSCLC. Zipalertinib +

  55. Slide 55: REZILIENT3: Interim Overall Survival Trend

    REZILIENT3: At Interim Analysis, Maturing OS Demonstrated a Positive Trend for Improvement in Overall Survival 100 Overall Survival Probability (%) 90 80 70 + Censor Z+C 60 Censor C 50 40 30 Zipalertinib + Chemotherapy: Chemotherapy: Hazard Ratio: 20 Total: 140 Total: 139 0.72 (95% CI, 0.42-1.23) 10

  56. Slide 56: REZILIENT3: Reduced Risk of Progression in Patients With Brain Metastases

    REZILIENT3: Zipalertinib Plus Chemotherapy Significantly Reduced the Risk of Disease Progression in Patients With Brain Metastases versus Chemotherapy Alone Zipalertinib + chemotherapy demonstrated more durable disease control and a greater PFS benefit in the high-risk population with a 0.38 HR. Zip

  57. Slide 57: REZILIENT3: Summary of Adverse Events

    REZILIENT3: Summary of Adverse Events (AEs) Zipalertinib + Chemotherapy Chemotherapy n (%) (n=140) (n=136) Treatment-Related Adverse Events (TRAEs) 138 (98.6) 120 (88.2) Grade ≥3 TRAEs 113 (80.7) 55 (40.4) Serious Adverse Events 71 (50.7) 45 (33.1) Treatment-related Serious Adverse Events 53 (37.9)

  58. Slide 58: REZILIENT3: Safety Profile

    REZILIENT3: Safety Profile • The safety profile of zipalertinib + chemotherapy was consistent with the known profile of the individual agents • The most common adverse events were chemotherapy-related cytopenias and EGFR-associated toxicities Zipalertinib + Chemotherapy Chemotherapy (n=140) (n=136)

  59. Slide 59: Profile of Zipalertinib Regimens Addresses Large Unmet Need

    Compelling Profile of Zipalertinib Regimens Creates Opportunity to Address Large Unmet Need Zipalertinib + Chemotherapy* Amivantamab + Chemotherapy1 Sunvozertinib monotherapy2 ORR 65.0% 73% 58.9% Median duration of response 14.2 months 9.7 months 11.2 months 1L Median PFS 14.5 months 11.4 months 10.

  60. Slide 60: Zipalertinib Plus Chemotherapy: Efficacy with a Manageable AE Profile

    Zipalertinib Plus Chemotherapy Achieves Compelling Efficacy with a Manageable AE Profile Zipalertinib + chemotherapy showed differentiated rates of EGFR related AEs Zipalertinib + Chemotherapy* Amivantamab + Chemotherapy1 Sunvozertinib monotherapy2 AEs associated with EGFR inhibition Any Grade (%) G

  61. Slide 61: Exon20 Insertions Is a Billion-Dollar Plus Commercial Opportunity in the U.S.

    Exon20 Insertions Is an Estimated Billion-Dollar Plus Commercial Opportunity in the U.S. Potential opportunities for $1B to $1.5B opportunity in the U.S.1 future revenue expansion ~4,500 treatable patients1 5,000 ~6,000+ treatable patients2 Estimated Annual Patients 4,000 Adjuvant NSCLC exon20ins 3,

  62. Slide 62: Taiho Zipalertinib Collaboration Provides Non-Dilutive Financial Benefits

    Taiho Zipalertinib Collaboration Provides Cullinan With Significant Non-Dilutive Financial Benefits Upfront Payment $275 million to Cullinan received in 2022 in exchange for worldwide rights to Taiho1 Milestone Payments Cullinan is eligible to receive $30 million and up to $100 million upon 2L and 1

  63. Slide 63: Zipalertinib Combination Therapy is Potentially Practice Changing

    Zipalertinib Combination Therapy is Potentially Practice Changing The compelling results support zipalertinib Regulatory combination therapy as a highly • 2L+: NDA for treatment of relapsed EGFR competitive regimen with the potential to exon20ins NSCLC under review by the U.S. FDA become a new SOC i

  64. Slide 64: Thank You

    THANK YOU

Cullinan Therapeutics — Investor Presentation (October 2026) on 6ix